메뉴 건너뛰기




Volumn 70, Issue 10, 2011, Pages 874-881

Prescription of TNF-alpha inhibitors and regional differences in 2010;Versorgung mit TNF-α-Blockern und regionale Unterschiede im Jahr 2010

Author keywords

Arthritis, rheumatoid; Biologicals; Prescription claims data; TNF inhibitors; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 83955161724     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-011-0873-8     Document Type: Article
Times cited : (9)

References (26)
  • 2
    • 84855507552 scopus 로고    scopus 로고
    • AkdÄ
    • AkdÄ (2010) Wirkstoff aktuell: Biologische DMARDs. http://www.akdae.de/Arzneimitteltherapie/WA/Archiv-Fertigarzneimittel/ Biologische-DMARDs.pdf
    • (2010) Wirkstoff Aktuell: Biologische DMARDs
  • 3
    • 16844381697 scopus 로고    scopus 로고
    • Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: A review
    • DOI 10.1016/j.autrev.2004.08.004
    • Atzeni F, Sarzi-Puttini P, Doria A et al (2005) Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev 4(3):144-152 (Pubitemid 40488743)
    • (2005) Autoimmunity Reviews , vol.4 , Issue.3 , pp. 144-152
    • Atzeni, F.1    Sarzi-Puttini, P.2    Doria, A.3    Iaccarino, L.4    Capsoni, F.5
  • 4
    • 84855491515 scopus 로고    scopus 로고
    • Medikamentöse Therapie der frühen rheumatoiden Arthritis: Rheuma-Versorgung regional unterschiedlich
    • Bensing C, Kleinfeld A (2009) Medikamentöse Therapie der frühen rheumatoiden Arthritis: Rheuma-Versorgung regional unterschiedlich. Monitor Versorgungsforschung 2(3):10-11
    • (2009) Monitor Versorgungsforschung , vol.2 , Issue.3 , pp. 10-11
    • Bensing, C.1    Kleinfeld, A.2
  • 5
    • 84855473962 scopus 로고    scopus 로고
    • DeutschesApothekenPortal
    • DeutschesApothekenPortal (2011) Rabattvertrags-Check. http://www.deutschesapothekenportal.de/apo-pzncheck.html
    • (2011) Rabattvertrags-Check
  • 6
    • 79960055269 scopus 로고    scopus 로고
    • Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label
    • Diaz-Lagares C, Perez-Alverez R, Garcia-Hernandez FJ et al (2011) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 13(4):R112
    • (2011) Arthritis Res Ther , vol.13 , Issue.4
    • Diaz-Lagares, C.1    Perez-Alverez, R.2    Garcia-Hernandez, F.J.3
  • 10
    • 69849085911 scopus 로고    scopus 로고
    • Sparen, koste es, was es wolle: Rabattverträge aus Versichertensicht
    • Hoffmann F, Windt R, Glaeske G (2009) Sparen, koste es, was es wolle: Rabattverträge aus Versichertensicht. Krankenversicherung 61(2):35-38
    • (2009) Krankenversicherung , vol.61 , Issue.2 , pp. 35-38
    • Hoffmann, F.1    Windt, R.2    Glaeske, G.3
  • 11
    • 84902129458 scopus 로고    scopus 로고
    • Versorgung mit Krebstherapeutika im Jahr 2010
    • Glaeske G, Schicktanz C (Hrsg) Asgard, St. Augustin
    • Hoffmann F (2011) Versorgung mit Krebstherapeutika im Jahr 2010. In: Glaeske G, Schicktanz C (Hrsg) BARMER GEK Arzneimittelreport 2011. Asgard, St. Augustin, S243-257
    • (2011) BARMER GEK Arzneimittelreport 2011
    • Hoffmann, F.1
  • 12
    • 79951863583 scopus 로고    scopus 로고
    • Zytostatikarezepturen in der ambulant-ärztlichen Versorgung
    • Hoffmann F, Glaeske G, Windt R (2011) Zytostatikarezepturen in der ambulant-ärztlichen Versorgung. Onkologe 17(1):55-60
    • (2011) Onkologe , vol.17 , Issue.1 , pp. 55-60
    • Hoffmann, F.1    Glaeske, G.2    Windt, R.3
  • 13
    • 79960258635 scopus 로고    scopus 로고
    • Diabetes prevalence based on health insurance claims: Large differences between companies
    • Hoffmann F, Icks A (2011) Diabetes prevalence based on health insurance claims: large differences between companies. Diabet Med 28(8):919-923
    • (2011) Diabet Med , vol.28 , Issue.8 , pp. 919-923
    • Hoffmann, F.1    Icks, A.2
  • 14
    • 84855481246 scopus 로고    scopus 로고
    • Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors
    • [Epub ahead of print]
    • Hoffmann F, Icks A (2011) Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen [Epub ahead of print]
    • (2011) Gesundheitswesen
    • Hoffmann, F.1    Icks, A.2
  • 15
    • 82155188444 scopus 로고    scopus 로고
    • Biosimilars: A regulatory perspective from America
    • Kay J (2011) Biosimilars: a regulatory perspective from America. Arthritis Res Ther 13(3):112
    • (2011) Arthritis Res Ther , vol.13 , Issue.3 , pp. 112
    • Kay, J.1
  • 16
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimumab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial
    • DOI 10.1002/art.20217
    • Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled. Arthritis Rheum 50(5):1400-1411 (Pubitemid 38608061)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.5 , pp. 1400-1411
    • Keystone, E.C.1    Kavanaugh, A.F.2    Sharp, J.T.3    Tannenbaum, H.4    Hua, Y.5    Teoh, L.S.6    Fischkoff, S.A.7    Chartash, E.K.8
  • 17
    • 79961111305 scopus 로고    scopus 로고
    • Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of longterm data
    • Keystone EC (2011) Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of longterm data. J Rheumatol 38(8):1552-1562
    • (2011) J Rheumatol , vol.38 , Issue.8 , pp. 1552-1562
    • Keystone, E.C.1
  • 20
    • 79952253563 scopus 로고    scopus 로고
    • Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009
    • Neovius M, Sundström A, Simard J et al (2011) Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 40(1):8-15
    • (2011) Scand J Rheumatol , vol.40 , Issue.1 , pp. 8-15
    • Neovius, M.1    Sundström, A.2    Simard, J.3
  • 21
    • 78649723958 scopus 로고    scopus 로고
    • Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: Results from the optimization of adalimumab trial
    • Pease C, Pope JE, Thorne C et al (2010) Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. J Rheumatol 37(12):2469-2474
    • (2010) J Rheumatol , vol.37 , Issue.12 , pp. 2469-2474
    • Pease, C.1    Pope, J.E.2    Thorne, C.3
  • 24
    • 60749125474 scopus 로고    scopus 로고
    • Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
    • Strangfeld A, Listing J, Herzer P et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737-744
    • (2009) JAMA , vol.301 , Issue.7 , pp. 737-744
    • Strangfeld, A.1    Listing, J.2    Herzer, P.3
  • 26
    • 83955165846 scopus 로고    scopus 로고
    • Biologicals und biosimilars
    • Glaeske G, Schicktanz C (Hrsg) Asgard St. Augustin
    • Windt R (2011) Biologicals und Biosimilars. In: Glaeske G, Schicktanz C (Hrsg) BARMER GEK Arzneimittelreport 2011. Asgard, St. Augustin, S113-129
    • (2011) BARMER GEK Arzneimittelreport 2011
    • Windt, R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.